---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-031563"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:00:37.568736+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elicio reports ELI-002 7P Phase 1a DFS not yet reached at 4.9mg; biomarker responders have no progression

## Summary
- Median DFS not reached in 14 patients; median follow-up 29.1 weeks.
- At 4.9mg AMP-peptide (n=8), median DFS not reached vs 12.6 weeks for 1.4mg (n=6).
- Patients with tumor biomarker reduction had zero progression events; non-responders had median DFS 11.0 weeks.
- Above-median T cell responders had no progression events as of May 24, 2024 data cutoff.
- Phase 2 interim analysis (135 patients) expected Q1 2025.

## SEC filing metadata
- accession: 0001140361-24-031563
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000114036124031563/0001140361-24-031563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000114036124031563/ny20031755x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-031563
- JSON: https://secwatch.observer/filing/0001140361-24-031563.json
- Plain text: https://secwatch.observer/filing/0001140361-24-031563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.